FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera

August 28, 2026 6:40 PM

Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) has received U.S. Food and Drug Administration approval for Mimrylo (rusfertide), a treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found